Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Abrdn Physical Platinum Shares ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Abrdn Physical Platinum Shares ETF trades at $14.33. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | PPLT | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $28.06 | $25.23 |
52-Week Low | $20.06 | $11.78 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
PPLT, the Aberdeen Physical Platinum Shares ETF, trades at $14.83, up 0.75% on the day, amid a bearish technical outlook with moving averages signaling sell pressure. The fund recently executed a 1-for-10 stock split effective May 18, 2026, adjusting share count without altering the underlying asset value. Key financial ratios are unavailable, as the ETF holds physical platinum, not generating traditional corporate earnings or sales.
The outlook for PPLT hinges on platinum price trends, which face headwinds from weaker industrial demand and competition from gold. Recent news highlights platinum's underperformance versus other precious metals, suggesting cautious sentiment. Risks include commodity volatility and economic cycles, while potential upside relies on a sustained rally in platinum markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
